50
Participants
Start Date
September 30, 2005
Primary Completion Date
November 30, 2007
PTK787
Visudyne® + PTK787, 500 mg/day
PTK787
Visudyne® + PTK787 1000 mg/day
Placebo
Visudyne® + Placebo
Novartis Investigational Site, Sydney
Novartis Investigative Site, Westmead
Novartis Investigative Site, Parramatta
Novartis Investigative Site, East Melbourne
Wilmer Eye Institute, Baltimore
Springfield Clinic, LLP, Springfield
Porter Adventist Hospital, Eye Lab, Denver
Retina-Vitreous Associates Medical Group, Beverly Hills
USF Eye Institute, Tampa
Lahey Clinic Medical Center, Eye institute, Peabody
Black Hills Regional Eye Institute, Rapid City
Lead Sponsor
Novartis
INDUSTRY